Tutorials
TG Therapeutics Inc logo

TG Therapeutics Inc

$ 8.31 +0.79 (+10.51%) 08:09 PM EST
P/E:
At Loss
P/B:
9.35
Market Cap:
$ 1.21B
Enterprise V:
$ 1.09B
Volume:
4.23M
Avg Vol (2M):
3.15M
Also Trade In:
Volume:
4.23M
Market Cap $:
1.21B
PE Ratio:
At Loss
Avg Vol (2-Month):
3.15M
Enterprise Value $:
1.09B
PB Ratio:
9.35
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

TG Therapeutics Inc
NAICS : 325412 SIC : 2834
2 Gansevoort Street, 9th Floor, New York, NY, USA, 10014
Description
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
Name Current Vs Industry Vs History
Cash-To-Debt 2.43
Equity-to-Asset 0.51
Debt-to-Equity 0.62
Debt-to-EBITDA -0.29
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -4.99
Distress
Grey
Safe
Beneish M-Score -0.83
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 75.33
9-Day RSI 71.05
14-Day RSI 67.76
6-1 Month Momentum % -45.6
12-1 Month Momentum % -74.94

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.68
Quick Ratio 4.68
Cash Ratio 4.52
Days Sales Outstanding 49.24

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.5

Financials (Next Earnings Date:2022-11-04 Est.)

TGTX's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:TGTX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 6.961
EPS (TTM) ($) -2.16
Beta 2.25
Volatility % 97.5
14-Day RSI 67.76
14-Day ATR ($) 0.701175
20-Day SMA ($) 6.6245
12-1 Month Momentum % -74.94
52-Week Range ($) 3.48 - 35.94
Shares Outstanding (Mil) 145.27

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

TG Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More